Targeting the bone microenvironment in multiple myeloma
GD Roodman - Journal of bone and mineral metabolism, 2010 - Springer
Journal of bone and mineral metabolism, 2010•Springer
Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent
development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone
pain. In the past few years several potential factors involved in this process have been
identified and, with the increased knowledge of the signaling pathways involved in the
regulation of normal osteoblast and osteoclast function, have provided us with a better
understanding of the contributions of the marrow microenvironment to MM bone disease …
development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone
pain. In the past few years several potential factors involved in this process have been
identified and, with the increased knowledge of the signaling pathways involved in the
regulation of normal osteoblast and osteoclast function, have provided us with a better
understanding of the contributions of the marrow microenvironment to MM bone disease …
Abstract
Multiple myeloma (MM) is a plasma cell malignancy characterized by the frequent development of osteolytic lesions, osteopenia, pathological fractures, and/or severe bone pain. In the past few years several potential factors involved in this process have been identified and, with the increased knowledge of the signaling pathways involved in the regulation of normal osteoblast and osteoclast function, have provided us with a better understanding of the contributions of the marrow microenvironment to MM bone disease. These studies have identified several potential novel targets for treating MM bone disease in addition to the current standard treatment of bisphosphonates. In this article, we discuss several potential targets for treating MM bone disease as well as novel therapies that are in clinical trials for these patients.
Springer
